SOUTH SAN FRANCISCO, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Genentech, Inc. invites investors, the media and the general public to listen to an audio webcast discussing Lucentis(TM) (ranibizumab) data presented at the Macula 2006 Meeting in New York City.
One-year data from the Phase III ANCHOR study of Lucentis in patients with wet age-related macular degeneration will be presented during an afternoon session on January 14, 2006.
The webcast will begin at 3:00 p.m. Pacific Time on January 14, 2006 and will be archived until 5:00 p.m. Pacific Time on January 21, 2006. An audio telephone replay will also be available beginning at 6:00 p.m. Pacific Time on January 14, 2006 through 5:00 p.m. Pacific Time on January 21, 2006. Access numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); Conference ID number is 3976320.
About Genentech
Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from, or are based on, Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States, and receives royalties or other income from companies that are licensed to market its products outside of the United States. The company has headquarters in South San Francisco, Calif., and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com .
Media Contact: Dawn Kalmar 650-225-5873
Investor Contact: Diane Schrick 650-225-1599
Genentech, Inc.
CONTACT: media, Dawn Kalmar, +1-650-225-5873, or investors, Diane Schrick,+1-650-225-1599, both of Genentech, Inc.
Web site: http://www.gene.com/
